Oxford BioDynamics (LON:OBD – Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported GBX (0.10) earnings per share for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative net margin of 825.61% and a negative return on equity of 451.74%.
Oxford BioDynamics Trading Up 17.8%
Shares of OBD stock traded up GBX 0.02 during trading hours on Friday, reaching GBX 0.11. 18,351,965 shares of the stock were exchanged, compared to its average volume of 16,501,012. Oxford BioDynamics has a 12-month low of GBX 0.08 and a 12-month high of GBX 0.78. The company has a current ratio of 2.01, a quick ratio of 2.80 and a debt-to-equity ratio of 131.61. The company’s 50-day moving average price is GBX 0.18 and its 200-day moving average price is GBX 0.22. The firm has a market capitalization of £4.55 million, a price-to-earnings ratio of -0.13 and a beta of 0.42.
About Oxford BioDynamics
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Further Reading
- Five stocks we like better than Oxford BioDynamics
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
